Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ENDP]

Reports for Purchase

Showing records 301 - 312 ( 312 total )

Industry: Medical - Drugs

Record: 301

01/12/2011

Daily Note

Pages: 19

Previewing the Quarter - 4Q10

Provider: DUNCAN-WILLIAMS, INC.

Analyst: RIVKIND I

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 302

01/10/2011

Company Report

Pages: 12

Switch strategy still expected

Provider: DAWSON JAMES SECURITIES, INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 303

12/28/2010

Company Report

Pages: 17

Reiterating Strong Buy Ahead of Catalysts

Provider: DUNCAN-WILLIAMS, INC.

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 304

09/28/2010

Company Report

Pages: 2

Potential Upside from Opana TRF - BUY

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 305

08/20/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 306

08/13/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences.

Provider: WEDBUSH SECURITIES INC.

Analyst: BANK P

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 307

08/12/2010

Company Report

Pages: 4

Earnings Boost From Penwest Deal

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 308

08/05/2010

Company Report

Pages: 4

acquired urology and endocrinology drug manufacturer Indevus Pharmaceuticals

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 309

06/24/2010

Industry Report

Pages: 10

PECIALTY PHARMACEUTICALS:Do Your Homework Over the Summer Because the Fall Will Be Explosive with Major PDUFA Activity

Provider: WEDBUSH SECURITIES INC.

Analyst: BANK P

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 310

04/23/2010

Topic Report

Pages: 5

The Week Ahead in Life Sciences : Upcoming Events for the Week of April 25

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 311

03/30/2010

Company Report

Pages: 5

Maintaining NEUTRAL Rating Given Takeaways from Recent Management Meeting; but Increasing PT to $25/share.

Provider: WEDBUSH SECURITIES INC.

Analyst: BANK P

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 312

01/19/2010

Industry Report

Pages: 38

Life Sciences - Biotechnology - Biotech Balance Sheet

Provider: MERRIMAN CURHAN FORD & CO.

Price: 75.00

Research Provided by a Third Party